Status:
COMPLETED
Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy
Lead Sponsor:
Cytos Biotechnology AG
Conditions:
Rhinoconjunctivitis
Allergies
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to test whether vaccinations with CYT003-QbG10 can improve allergy symptoms in patients with house dust mite allergy. The active treatment will be compared against placebo.
Eligibility Criteria
Inclusion
- Perennial allergic rhinoconjunctivitis due to clinically relevant allergy towards house dust mite allergens
- Further criteria as defined in the study protocol
Exclusion
- Clinically manifested seasonal allergy/-ies which is/are expected to interfere with the patient's study treatment schedule and/or assessments
- Clinically relevant perennial allergy/-ies other than house dust mites allergy
- Contraindication to any study test or procedure
- Further criteria as defined in the study protocol
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2010
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00800332
Start Date
November 1 2008
End Date
November 1 2010
Last Update
November 15 2010
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Cytos Investigator Sites
Paide, Tartu, Tallin, Rakvere, Estonia
2
Cytos Investigator Sites
Fulda, Dresden, Ulm, Rodgau, Kassel, Eisenach, Germany
3
Cytos Investigator Sites
Wiesbaden, Frankfurt/M, Leipzig, Jena, Hamburg, Dulmen, Germany
4
Cytos Investigator Sites
N. Faliro, Hiraklion, Athens, Greece